Navigation Links
Valeant Pharmaceuticals Announces Redemption Of The Remaining $465.5 Million Aggrerate Principal Amount Of Its Outstanding 6.50% Senior Notes Due 2016
Date:12/2/2013

LAVAL, Quebec, Dec. 2, 2013 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced that its wholly owned subsidiary, Valeant Pharmaceuticals International, will redeem the remaining $465.5 million aggregate principal amount of its outstanding 6.50% Senior Notes due 2016 CUSIP Nos. 91911XAR5, U9098VAH5 (the "Notes") and has mailed an irrevocable notice of redemption for the Notes. On November 15, 2013, Valeant Pharmaceuticals International mailed an irrevocable notice of redemption for $450 million aggregate principal amount of the Notes.

On December 2, 2013, a copy of the irrevocable notice of redemption with respect to the remaining Notes was mailed to record holders of the Notes by The Bank of New York Mellon Trust Company, N.A., 400 South Hope Street, Suite 400, Los Angeles, CA 90071, as trustee under the indenture governing the Notes.

This press release shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.  No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act.

About Valeant Pharmaceuticals International, Inc.
Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, eye health, neurology, and branded generics. More information about Valeant Pharmaceuticals International, Inc. can be found at

SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Valeant Pharmaceuticals Announces Pricing Of Private Offering Of Senior Notes
2. Valeant Pharmaceuticals Announced Redemption Of $450 Million Aggregate Principal Amount Of Its Outstanding 6.50% Senior Notes Due 2016
3. Valeant Pharmaceuticals Reports 2013 Third Quarter Financial Results
4. Valeant Pharmaceuticals Announces Settlement Agreement With Anacor
5. Valeant Pharmaceuticals Announces Partnership With National Coalition Against Domestic Violence
6. Valeant Pharmaceuticals Announces Continuance
7. Valeant Pharmaceuticals Reports 2013 Second Quarter Financial Results
8. Valeant Pharmaceuticals International, Inc. Completes Acquisition Of Bausch + Lomb
9. Valeant Pharmaceuticals To Announce 2013 Second Quarter Results On August 7, 2013
10. Valeant Pharmaceuticals Announces Closing of Public Offering of Common Shares
11. Valeant Pharmaceuticals Announces Exercise Of Over-Allotment Option
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 ... "Scintillator Market by Composition of Material, Application (Healthcare, ... others), End Product (Personal Instrument, Hand-Held Instruments, Fixed, ... and Analysis to 2013 - 2020", published by MarketsandMarkets, the ... CAGR of 5.62% from 2014 to 2020, and ...
(Date:7/11/2014)... 2014  Australian drug delivery company, Phosphagenics Limited (ASX: ... A$19.3 million via a placement of A$16.3 million to ... U.S., Asia and ... purchase plan (SPP) to be offered to existing shareholders. ... two tranches. "This capital raising positions us ...
(Date:7/11/2014)... , July 11, 2014 Research and ... of the "Immunoprotein Diagnostic Testing Market - ... highest CAGR of 6% and is expected to ... to their offering. ... diagnostic testing has been segmented according to immunoprotein ...
Breaking Medicine Technology:Scintillator Market will be worth $479.16 Million by 2020 2Scintillator Market will be worth $479.16 Million by 2020 3Scintillator Market will be worth $479.16 Million by 2020 4Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2
... for individuals living with West Nile Virus and ... or immune compromised, PURCHASE, N.Y., Sept. 9 ... State University supported by the Division of,Vector-Borne Infectious ... (CDC) has demonstrated that AHCC(R) (Active Hexose Correlated,Compound) ...
... SAN DIEGO, Sept. 9 Ardea Biosciences, Inc.,(Nasdaq: ... presented on,the Company,s lead mitogen-activated ERK kinase (MEK) inhibitor, ... at,the Gaylord Palms Resort & Convention Center in Orlando., ... follows:, Date/Time: Tuesday, October 7, 2008 from 10:30 ...
Cached Medicine Technology:Study Demonstrates That AHCC(R) Provides Immune Enhancement Against the West Nile Virus 2Study Demonstrates That AHCC(R) Provides Immune Enhancement Against the West Nile Virus 3Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at American College of Gastroenterology Annual Scientific Meeting 2
(Date:7/13/2014)... research in Nature Genetics identifies a ... that causes eosinophillic esophagitis (EoE), opening up potential ... food allergy. , EoE is a chronic ... triggered by allergic hypersensitivity to certain foods and ... cells called eosinophils (part of the body,s immune ...
(Date:7/13/2014)... Chromatography system is a physical method of separation ... samples such as air and water. Chromatography systems ... namely mobile phase and stationary phase. The components ... phase, followed by the differential rate of migration ... mixture. Chromatography system plays an important role in ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 Victorian Hotel ... by promoting the rental of bikes for its "Cycle ... downtown Victorian Hotel to tour the area using a ... tax. Bicycle enthusiasts love to call Vancouver home, as ... for cycle travel and picturesque journeys through the countryside. ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 Micro irrigation ... ensure proper water dispersal as wells as to maintain ... agriculture is projected to become a dominant revenue generator ... sophisticated methods to reduce resource costs has led to ... and plantations, and has further caused massive demand for ...
(Date:7/13/2014)... 13, 2014 Advanced boilers are ... least amount of fossil fuels, produce high-capacity power, ... to increased global warming and climate change concerns, ... reduce harmful gas emissions and pollutants coming from ... in the global advance boilers market., The global ...
Breaking Medicine News(10 mins):Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 2Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 3Health News:North America Chromatography Systems Market Is Expected to Reach $6593.4 Million by 2018 - New Report by MicroMarket Monitor 2Health News:North America Chromatography Systems Market Is Expected to Reach $6593.4 Million by 2018 - New Report by MicroMarket Monitor 3Health News:Victorian Hotel Creates Excitement by Adding "Cycle the City" Bike Rentals for Its Vancouver Hotel Rooms 2Health News:Agricultural Micro Irrigation System Market is Expected to Grow at a CAGR of 18.1%, from 2013 to 2018 - New Report by MicroMarket Monitor 2Health News:Agricultural Micro Irrigation System Market is Expected to Grow at a CAGR of 18.1%, from 2013 to 2018 - New Report by MicroMarket Monitor 3Health News:North America Advanced Boilers Market is Expected to Reach $518.7billion by 2019 - New Report by MicroMarket Monitor 2Health News:North America Advanced Boilers Market is Expected to Reach $518.7billion by 2019 - New Report by MicroMarket Monitor 3
... MATEO, Calif., Feb. 28 NeurogesX, Inc.,(Nasdaq: ... and,commercializing novel pain management therapies, announced today that,Anthony ... to a,panel focused on pain management at Susquehanna ... Conference. Mr. DiTonno,is scheduled to present on Tuesday, ...
... latest technologies and ... medical advancements, AUSTIN, Texas, ... hospital, officially opened the expansion of its,heart hospital today with the ... rated as the number one overall,cardiac program in the State of ...
... diagnose severity of bipolar illness , , THURSDAY, Feb. 28 ... mood disorders have been identified by Indiana University School ... the way bipolar illness is diagnosed and treated. , ... found varying levels of the biomarkers in participants with ...
... (TSX: MDS; NYSE:,MDZ), a leading provider of products ... that the Company will report first quarter,results for ... will also host an analyst conference call with ... Douglas Prince,Executive Vice-President Finance and Chief Financial Officer, ...
... to $977.3mm for Full Year; Up 27% to $268.0mm for ... Fourth Quarter, - Adjusted EPS (incl. Stock Compensation) Up ... for Fourth Quarter (GAAP EPS ... up 62% to $0.47), - Continuing New Win Momentum and Pipeline Strengthening Across Segments, - ...
... 28 Cardiva Medical, Inc., a,privately held medical ... announces that it will present the highlights of ... 9:20am at the Medtech,Insight/Windhover Information,s "Investment In Innovation ... at The,Venetian in Las Vegas, NV., The ...
Cached Medicine News:Health News:NeurogesX to Present at Susquehanna Financial Group's 2nd Annual SIGnificant Options in Healthcare Conference 2Health News:NeurogesX to Present at Susquehanna Financial Group's 2nd Annual SIGnificant Options in Healthcare Conference 3Health News:Heart Hospital of Austin's Expansion Increases Patient Capacity by 30 Percent 2Health News:Heart Hospital of Austin's Expansion Increases Patient Capacity by 30 Percent 3Health News:Heart Hospital of Austin's Expansion Increases Patient Capacity by 30 Percent 4Health News:Biomarkers for Mood May Alter Psychiatric Treatments 2Health News:inVentiv Health Reports Record Financial Results for Fourth Quarter and Full Year 2007 2Health News:inVentiv Health Reports Record Financial Results for Fourth Quarter and Full Year 2007 3Health News:inVentiv Health Reports Record Financial Results for Fourth Quarter and Full Year 2007 4Health News:inVentiv Health Reports Record Financial Results for Fourth Quarter and Full Year 2007 5Health News:inVentiv Health Reports Record Financial Results for Fourth Quarter and Full Year 2007 6Health News:inVentiv Health Reports Record Financial Results for Fourth Quarter and Full Year 2007 7Health News:inVentiv Health Reports Record Financial Results for Fourth Quarter and Full Year 2007 8Health News:inVentiv Health Reports Record Financial Results for Fourth Quarter and Full Year 2007 9Health News:inVentiv Health Reports Record Financial Results for Fourth Quarter and Full Year 2007 10Health News:inVentiv Health Reports Record Financial Results for Fourth Quarter and Full Year 2007 11Health News:inVentiv Health Reports Record Financial Results for Fourth Quarter and Full Year 2007 12Health News:inVentiv Health Reports Record Financial Results for Fourth Quarter and Full Year 2007 13Health News:inVentiv Health Reports Record Financial Results for Fourth Quarter and Full Year 2007 14Health News:inVentiv Health Reports Record Financial Results for Fourth Quarter and Full Year 2007 15Health News:Cardiva Medical, Inc. to Present Highlights of the Boomerang Catalyst(TM) II System at the 'Investment in Innovation (In3) West' Conference on February 29, 2008 in Las Vegas, NV 2
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of cardiac troponin I (cTnl) in human whole blood and serum specimens...
Medicine Products: